Table 1.

Mesonephric carcinosarcomas in the literature and the present case

Patient no	Age (years)	Clinical presentation	Figo stage	Sarcomatous component	Surgical treatment	Adjuvant therapy	Outcome	Follow-up/mean overall survival
113	65	PMB	Ib	Spindle cells; osteosarcoma	RAH, BSO	RT	NED	23 months
21	37	Postcoital bleeding	Ib	Spindle cells	HT, BSO, LD	ChT	AWD	11 months
31	40	AUB	Ib	Spindle cells	HT, BSO	RT	NED	2.3 years
41	73	AUB+cervical polyp	Ib	Spindle cells	HT, BSO	RT	NED	3 years
51 2	39	AUB	Ib	Spindle cells;osteosarcoma	HT, BSO		DOD	6.2 years
69	54	PMB	IIa	Spindle cells	HT, SBO, LD, omentectomy		DOD	7 months
79	54	NA	Ib	Spindle cells; chondrosarcoma	HT, BSO, LD, omentectomy		NED	13 months
89	62	NA	IVb	Spindle cells; rhabdomyosarcoma	HT, SOB, LD	RT	AWD	36 months
95	63	PMB	IIa	Spindle cells	RAH, BSO, LD		NED	10 months
106	59	Tumour rupture	IIIb	Spindle cells	HT, SOB, LD	ChT, RT	NED	4 months
11(our case)	64	PMB + cervical polyp	IIa	Endometrial stroma sarcoma	RAH, BSO, LD omentectomy	ChT, RT	DOD	7 months

AUB, abnormal uterine bleeding; AWD, alive with disease; BSO, bilateral salpingo-oophorectomy; ChT, chemotherapy; DOD, died of disease; HT, hysterectomy; LD, lymphadenectomy; NA, not available; NED, no evidence of disease; PMB, postmenopausal bleeding; RAH, radical hysterectomy; RT, radiotherapy.